What is CDKL5 Deficiency Disorder?
CDKL5 Deficiency Disorder (CDD) is a rare X-linked genetic brain disorder caused by pathogenic variants in the cyclin-dependent kinase-like 5 (CDKL5) gene. Affected infants typically develop seizures within the first few months of life, accompanied by severe neurodevelopmental impairments including limited motor function, absence of speech, and profound cognitive deficits, resulting in lifelong severe disability. The estimated incidence ranges from 1 in 40,000 to 1 in 60,000 live births.
Pathogenesis
CDD is primarily caused by loss-of-function mutations in the CDKL5gene, which encodes a kinase critical for neuronal development. Under physiological conditions, CDKL5 regulates neuronal morphogenesis, synaptic plasticity, and gene transcription by phosphorylating various substrates. Its core mechanism involves recognizing and phosphorylating a specific “RXPXS/T” consensus motif on target proteins, thereby modulating downstream signaling pathways.
When CDKL5 function is lost, this precise phosphorylation network is disrupted, leading to cytoskeletal dynamics imbalance. This results in aberrant axonal growth, reduced dendritic branching, and impaired excitatory synaptic transmission. Furthermore, CDKL5 plays a key role in DNA double-strand break repair by phosphorylating DNA damage response proteins such as ELOA and EP400, recruiting repair complexes to damage sites. CDKL5deficiency leads to decreased genomic stability in neurons and accumulation of DNA damage, ultimately exacerbating neuronal apoptosis and degeneration. These molecular events underlie the early developmental delay, epilepsy, and severe neurological phenotypes observed in patients.
Common Preclinical Mouse Models
Research on CDD relies heavily on preclinical animal models that closely recapitulate human pathology. Three widely used CDD mouse models are:
- Cdkl5 KO Mice: Global deletion of the Cdkl5gene recapitulates neurodevelopmental and cognitive phenotypes including impaired motor coordination (rotarod test), reduced sociability, working memory deficits, and decreased dendritic spine density. However, these mice typically do not exhibit spontaneous epileptic seizures and are primarily used for basic mechanistic studies.
- Cdkl5 R59X Point Mutant Mice: Introduction of a common nonsense mutation (CDKL5 c.175C>T, p.R59X) produces a truncated protein and triggers nonsense-mediated mRNA decay. In addition to reproducing motor, social, and learning/memory deficits, these mice develop spontaneous epileptic spasms, making them widely used for anti-epileptic drug evaluation.
- Cdkl5 Conditional Knockout Mice: Selective deletion of Cdkl5in forebrain glutamatergic neurons is primarily used to dissect cell-type-specific mechanisms and recapitulates learning and memory deficits.
Supporting Gene Therapy
Gene therapy offers hope for rare diseases, but its development and validation depend on precise animal model support. MingCeler Biotech, leveraging its self-developed TurboMice™ technology, has developed multiple rare disease mouse models. TurboMice™ technology overcomes the technical challenges of long mouse model generation cycles and low success rates for complex models, enabling editing at almost any target gene locus. By skipping breeding and screening, complete homozygous gene-edited mouse models can be prepared directly from embryonic stem cells in as little as 2 months.
MingCeler Biotech can customize various CDD mouse models according to client needs, such as Cdkl5 KO mice, Cdkl5 R59X point mutant mice, and Cdkl5 conditional knockout mice. Inquiries are welcome.
Reference:
Van Bergen NJ, Massey S, Quigley A, Rollo B, Harris AR, Kapsa RMI, Christodoulou J. CDKL5 deficiency disorder: molecular insights and mechanisms of pathogenicity to fast-track therapeutic development. Biochem Soc Trans. 2022 Aug 31;50(4):1207-1224. doi: 10.1042/BST20220791. PMID: 35997111; PMCID: PMC9444073.